Antibody Drug Triggers Tumor Disappearance in Early Trial

In a small study, two patients with metastatic cancer who received an engineered antibody that targets CD40, a protein that plays an important role in the immune system, experienced complete remission. It’s an “encouraging moment,” according to Gregory Beatty, MD, PhD, an associate professor of Hematology-Oncology, who was not involved in the study. “We really need to figure out how to bring this type of therapy to the right patients in the right setting,” he said.